Capricor Shares Rebound After Hours as CEO Signals Deramiocel BLA Nears FDA Verdict
Capricor Therapeutics (CAPR) shares rose 5% after-hours as CEO Linda Marbán indicated the FDA's decision on its deramiocel BLA is due Nov. 22. The company reported a Q3 net loss of $42.7M, up from $24.6M a year earlier, with no revenue. The FDA decision could significantly impact the company's future, as deramiocel is a potential first-in-class treatment for upper-limb function in Duchenne muscular dystrophy patients.
How this was made
The 30-second read
Why it matters
The final‑stage BLA filing and after‑hours price rally signal heightened market focus; the upcoming decision is a make‑or‑break event.
Market read
The FDA decision will be a decisive catalyst for CAPR and may influence sentiment in the rare‑disease biotech niche.
What to watch
Potential arbitration with Nippon Shinyaku may delay commercialization even if approved.
Background
Capricor Therapeutics is a clinical‑stage biotech with no revenue, developing deramiocel for upper‑limb function in Duchenne muscular dystrophy.
Ticker impact
CEO said the BLA for deramiocel is in the final FDA review stage with a decision deadline of Nov 22; shares rose ~5% in after‑hours trading.
likely upward pressure if approval appears, potential sharp drop on denial
Market has already priced some upside on the final‑stage review; the narrow decision window intensifies price sensitivity.
Market effects
Positive FDA momentum could lift other DMD‑focused biotech stocks.
US biotech sector may see increased volatility ahead of the decision.
Limited to investors tracking rare‑disease therapeutics worldwide.
Counterpoint
If the FDA seeks additional data, the stock could tumble sharply despite recent optimism.
Key entities
- companyCapricor Therapeutics
Developer of deramiocel, a DMD therapy.
- executiveLinda Marbán
CEO of Capricor, provided the BLA status update.
